Acute heart failure clinical drug development: From planning to proof of activity to phase III

Cardiology

Volumn 116, Issue 4, 2010, Pages 292-301

  Cotter, Gad ^a   Voors, Adriaan A ^b   Weatherley, Beth Davison ^a   Pang, Peter S ^c   Teerlink, John R ^a   Filippatos, Gerasimos ^a   Ponikowski, Piotr ^d   Milo Cotter, Olga ^a   Dittrich, Howard ^e   Teichman, Sam L ^f   Adams, Kirkwood F ^g   Gheorghiade, Mihai ^c   Metra, Marco ^h  

^a Momentum Research Inc   (United States)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c NORTHWESTERN UNIVERSITY   (United States)

^d WROCLAW MEDICAL UNIVERSITY   (Poland)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Corthera Inc ^*  (United States)

^g UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Acute heart failure; Breathlessness; Drug development

Indexed keywords

DIGOXIN; DIURETIC AGENT; HYPERTENSIVE FACTOR; INOTROPIC AGENT; ISTAROXIME; LEVOSIMENDAN; MILRINONE; NESIRITIDE; PLACEBO; RELAXIN; ROLOFYLLINE; TEZOSENTAN; TOLVAPTAN;

ACUTE HEART FAILURE; CLINICAL DECISION MAKING; CLINICAL FEATURE; CLINICAL RESEARCH; CLINICAL TRIAL; DISEASE EXACERBATION; DISEASE MARKER; DRUG EFFICACY; DRUG RESEARCH; DYSPNEA; EXPERIMENTAL MODEL; HEART MUSCLE INJURY; HUMAN; KIDNEY INJURY; LENGTH OF STAY; MORTALITY; NON INVASIVE PROCEDURE; NONHUMAN; PATIENT SAFETY; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ACUTE DISEASE; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; HEART FAILURE; HUMANS; RESEARCH DESIGN;

EID: 77957139942     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000318048     Document Type: Review

References (36)

1. Hunt SA, Abraham WT, Chin MH, et al: 2009 focused update incorporated into the ACC/ AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009; 53:e1-e90.
2. Dickstein K, Cohen-Solal A, Filippatos G, et al: ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology: developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29: 2388-2442.
3. Gheorghiade M, Abraham W, Albert N, et al: Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 2006; 296: 2217-2226.
4. Cotter G, Metra M, Weatherley BD, Dittrich HC, Massie BM, Ponikowski P, Bloomfield DM, O'Connor CM: Physician-determined worsening heart failure: a novel definition for early worsening heart failure in patients hospitalized for acute heart failure - association with signs and symptoms, hospitalization duration, and 60-day outcomes. Cardiology 2010; 115: 29-36.
5. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, Ganiats TG, Goldstein S, Gregoratos G, Jessup ML, Noble RJ, Packer M, Silver MA, Stevenson LW, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Jacobs AK, Hiratzka LF, Russell RO, Smith SC Jr, American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure), International Society for Heart and Lung Transplantation, Heart Failure Society of America. ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary - A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). Developed in collaboration with the International Society for Heart and Lung Transplantation. Endorsed by the Heart Failure Society of America. Circulation 2001; 104: 2996-3007. (Pubitemid 33139116)
6. Gheorghiade M, Pang PS: Acute heart failure syndromes. J Am Coll Cardiol 2009; 17: 557-573.
7. Filippatos G, Zannad F: An introduction to acute heart failure syndromes: definition and classification. Heart Fail Rev 2007; 12: 87-90. (Pubitemid 46916952)
8. Gheorghiade M, Adams KF, Cleland JG, Cotter G, Felker GM, Filippatos GS, Fona row GC, Greenberg BH, Hernandez AF, Khan S, Komajda M, Konstam MA, Liu PP, Maggioni AP, Massie BM, McMurray JJ, Mehra M, Metra M, O'Connell J, O'Connor CM, Pang PS, Piña IL, Sabbah HN, Teerlink JR, Udelson JE, Yancy CW, Zannad F, Stockbridge N, Acute Heart Failure Syndromes International Working Group: Phase III clinical trial end points in acute heart failure syndromes: a virtual roundtable with the Acute Heart Failure Syndromes International Working Group. Am Heart J 2009; 157: 957-970.
9. Givertz MM, Massie BM, Fields TK, Pearson LL, Dittrich HC, CKI-201 and CKI-202 Investigators: The effects of KW-3902, an adenosine A1-receptor antagonist, on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance. J Am Coll Cardiol 2007; 50: 1551-1560.
10. Ritter S, Rudiger A, Maggiorini M: Transpulmonary thermodilution-derived cardiac function index identifies cardiac dysfunction in acute heart failure and septic patients: an observational study. Crit Care 2009; 13:R133.
11. Fincke R, Hochman JS, Lowe AM, Menon V, Slater JN, Webb JG, LeJemtel TH, Cotter G, SHOCK Investigators: Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: a report from the SHOCK trial registry. J Am Coll Cardiol 2004; 44: 340-348.
12. Isaac DL: Biomarkers in heart failure management. Curr Opin Cardiol 2008; 23: 127-133.
13. Cohen-Solal A, Logeart D, Huang B, Cai D, Nieminen MS, Mebazaa A: Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure. J Am Coll Cardiol 2009; 53: 2343-2348.
14. Gheorghiade M, Pang PS: Are BNP changes during hospitalization for heart failure a reliable surrogate for predicting the effects of therapies on post-discharge mortality? J Am Coll Cardiol 2009; 53: 2349-2352.
15. Noveanu M, Mebazaa A, Mueller C: Cardiovascular biomarkers in the ICU. Curr Opin Crit Care 2009; 15: 377-383.
16. Fleming TR, DeMets DL: Surrogate end points in clinical trials: are we being misled? Ann Intern Med 1996; 125: 605-613.
17. Temple R: Are surrogate markers adequate to assess cardiovascular disease drugs? JAMA 1999; 282: 790-795.
18. Davison Weatherley B, Cotter G, Sun H, Chen L, Teerlink JR, Metra M, Felker GM, Voors AA, Ponikowski P, Teichman SL, Unemori E, Koch GG: Evaluation of potential treatment effect and dose selection across multiple clinical endpoints in a pilot study: results from Pre-RELAX-AHF. Submitted.
19. Teerlink JR, Metra M, Felker GM, Ponikowski P, Voors AA, Weatherley BD, Marmor A, Katz A, Grzybowski J, Unemori E, Teichman SL, Cotter G: Relaxin for the treatment of patients with acute heart failure (Pre-RELAXAHF): a multicentre, randomised, placebocontrolled, parallel-group, dose-finding phase IIb study. Lancet 2009; 373: 1429-1439.
20. Cotter G, Dittrich HC, Weatherley BD, Bloomfield DM, O'Connor CM, Metra M, Massie BM Protect Steering Committee Investigators and Coordinators: The PROTECT pilot study: a randomized, placebocontrolled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. J Card Fail 2008; 14: 631-640.
21. Cohn J, Cleland JG, Lubsen J, Borer JS, Steg PG, Perelman M, Zannad F: Unconventional end points in cardiovascular clinical trials: should we be moving away from morbidity and mortality? J Card Fail 2009; 15: 199-205.
22. Allen LA, Metra M, Milo-Cotter O, Filippatos G, Reisin LH, Bensimhon DR, Gronda EG, Colombo P, Felker GM, Cas LD, Kremastinos DT, O'Connor CM, Cotter G, Davison BA, Dittrich HC, Velazquez EJ: Improvements in signs and symptoms during hospitalization for acute heart failure follow different patterns and depend on the measurement scales used: an international, prospective registry to evaluate the evolution of measures of disease severity in acute heart failure (MEASURE-AHF). J Card Fail 2008; 14: 777-784.
23. Pang PS, Cleland JG, Teerlink JR, Collins SP, Lindsell CJ, Sopko G, Peacock WF, Fonarow GC, Aldeen AZ, Kirk JD, Storrow AB, Tavares M, Mebazaa A, Roland E, Massie BM, Maisel AS, Komajda M, Filippatos G, Gheorghiade M, Acute Heart Failure Syndromes International Working Group: A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: the need for a uniform approach. Eur Heart J 2008; 29: 816-824.
24. McMurray JJ, Teerlink JR, Cotter G, Bourge RC, Cleland JG, Jondeau G, Krum H, Metra M, O'Connor CM, Parker JD, Torre-Amione G, van Veldhuisen DJ, Lewsey J, Frey A, Rainisio M, Kobrin I, VERITAS Investigators: Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA 2007; 298: 2009-2019.
25. Cleland JG, Freemantle N, Coletta AP, Clark AL: Clinical trials update from the American Heart Association: REPAIRAMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur J Heart Fail 2006; 8: 105-110.
26. Cotter G, Metra M, Weatherley BD, Dittrich HC, Massie BM, Ponikowski P, Bloomfield DM, O'Connor CM: Physician-determined worsening heart failure: a novel definition for early worsening heart failure in patients hospitalized for acute heart failure - association with signs and symptoms, hospitalization duration, and 60-day outcomes. Cardiology 2010; 115: 29-36.
27. Braunstein JB, Anderson GF, Gerstenblith G, Weller W, Niefeld M, Herbert R, Wu AW: Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. J Am Coll Cardiol 2003; 42: 1226-1233.
28. Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, O'Connor CM, Pieper K, Sun JL, Yancy CW, Young JB, OPTIMIZE-HF Investigators and Hospitals: Factors identified as precipitating hospital admissions for heart failure and clinical outcomes: findings from OPTIMIZE- HF. Arch Intern Med 2008; 168: 847-854.
29. Stevenson LW, Hellkamp AS, Leier CV, Sopko G, Koelling T, Warnica JW, Abraham WT, Kasper EK, Rogers JG, Califf RM, Schramm EE, O'Connor CM: Changing preferences for survival after hospitalization with advanced heart failure. J Am Coll Cardiol 2008; 52: 1702-1708.
30. Allen LA, Hernandez AF, O'Connor CM, Felker GM: End points for clinical trials in acute heart failure syndromes. J Am Coll Cardiol 2009; 53: 2248-2258.
31. Cuffe MS, et al: Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002; 287: 1541-1547.
32. Packer M, et al: Effect of oral milrinone on mortality in severe chronic heart failure: the PROMISE Study Research Group. N Engl J Med 1991; 325: 1468-1475.
33. Cuffe MS, Califf RM, Adams KF Jr, Benza R, Bourge R, Colucci WS, Massie BM, O'Connor CM, Pina I, Quigg R, Silver MA, Gheorghiade M, Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIMECHF) Investigators: Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002; 287: 1541-1547.
34. Felker GM, Benza RL, Chandler AB, Leimberger JD, Cuffe MS, Califf RM, Gheorghiade M, O'Connor CM, OPTIME-CHF Investigators: Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME CHF study. J Am Coll Cardiol 2003; 41: 997-1003.
35. Sackner-Bernstein JD, Skopicki HA, Aaronson KD: Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005; 111: 1487-1491.
36. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K: Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 2005; 293: 1900-1905.